

Date: 31.10.2023

To

**Assistant Manager, Surveillance,
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051**

NSE Code: MEDICAMEQ

Subject: Reply to the Clarification sought on Price Movement

This is with reference to communication received from NSE vide email dated October 31, 2023 Ref No.: NSE/CM/Surveillance/13540 seeking clarification in significant price moment, we bring to the kind notice of the Exchange that there are no reportable events, information etc., that have a bearing on the operation/performance of the Company including price sensitive information which may result in the increase in the Prices of the shares of the Company under Regulation 30 of SEBI (LODR) Regulations, 2015.

The increase in the share price is purely market driven and the current market conditions; the management of the company is in no way connected with such increase in Price of shares.

Please be rest assured that the Company would always comply with the reporting requirements of the stock exchanges as provided in Regulations 30 of SEBI (LODR) Regulations, 2015, wherever applicable.

Kindly take the same on your records and oblige.

Thanking You

Yours truly,
For Medicamen Biotech Limited

**Parul Choudhary
Company Secretary & Compliance Officer
ACS: 44157**